| ★ | Sotatercept May Improve RV Function in Group 3 3 Pulmonary Hypertension | | 112 | Estados Unidos | |
| 15 | Idiopathic Pulmonary Fibrosis - Treatment and New Hope | MedCram - Medical Lectures Explained CLEARLY @medcram | 9.0K | Estados Unidos | 85 |
| 2 | Étude CADENCE : Résultats prometteurs pour le sotatercept dans une forme rare d'HTAP | Cardio-online @cardio-online9873 | 2.3K | Francia | 90 |
| 14 | Efdoralprin Alfa Normalizes Alpha-1 Antitrypsin Levels I #ats2026 | | 548 | Estados Unidos | 85 |
| 20 | La Universitat se suma al Dia Europeu de Dèficit d'Alfa-1 | Universitat de València @universitatvalencia | 481 | España | 85 |
| 9 | Inhaled Treprostinil for IPF: TETON-1 Phase 3 Results With Steven Nathan, MD | ATS 2026 | | 301 | Estados Unidos | 86 |
| 3 | Ralinepag Cuts PAH Clinical Worsening Risk by 55%, With Vallerie McLaughlin, MD | ATS 2026 | | 290 | Estados Unidos | 87 |
| 1 | Sotatercept May Improve Right Heart Function in #pulmonaryhypertension | | 232 | Estados Unidos | 96 |
| 8 | Avances terapéuticos en Hipertensión Pulmonar y su impacto en pacientes con comorbilidades | | 209 | Argentina | 86 |
| 17 | Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results | | 156 | Estados Unidos | 85 |
| 18 | Demystifying Evidence for Antiplatelet De-escalation in ASCVD | Matt Lillyblad, PharmD, BCCCP, BCCP | Minneapolis Heart Institute Foundation @mplsheartinstfound | 117 | Estados Unidos | 85 |
| 5 | Rethinking Advanced Heart Failure: Treat the Disease, Not the Symptoms | | 110 | Estados Unidos | 87 |
| 7 | AERIFY: Phase 3 Data Reveal Challenges, Potential of Itepekimab in COPD | | 105 | Estados Unidos | 87 |
| 19 | SYMPHONY-PE: Early Thrombectomy Improves Pulmonary Embolism Outcomes | | 86 | Estados Unidos | 85 |
| 13 | Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results | | 82 | Estados Unidos | 85 |
| 11 | Hipertensión pulmonar en Puerto Rico : Diagnóstico tardío y factores de riesgo | | 69 | Puerto Rico | 86 |
| 10 | Functional Air Trapping May Predict Pneumothorax After BLVR | | 56 | Estados Unidos | 86 |
| 12 | ATS 2026 Pulmonology: AD109, Ralinepag, ALIS, Itepekimab & More | HCPLive Expert Interviews | | 55 | Estados Unidos | 85 |
| 6 | Screening and treatment of systemic sclerosis-associated PAH: where do we stand in 2024? | | 53 | — | 87 |
| 4 | SGLT2 Inhibitors May Reduce COPD Readmissions I ATS 2026 | | 48 | Estados Unidos | 87 |
| 16 | Helping Patients Breathe Easier | Lynn Bingaman, CRNP at Geisinger | Geisinger @geisingerhealth | 45 | Estados Unidos | 85 |